Lu-PSMA-617 (177Lu-PSMA-617)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Lu-PSMA-617 (177Lu-PSMA-617), covering 2025-12-31 to 2025-12-31. Get the full timeline:
Most recent: Clinical Trial Update: Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer [NA]